Internal Medicine, Endocrinology, Diabetes, & Metabolism · Gloucester, MA
NPI
1558308205
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
0
Medicare group memberships
Hospitals
5
Hospital affiliations
298 Washington St, Addison Gilbert Hospital
Gloucester, MA, 01930
Phone (978) 283-4000
Medicare paid, 2024
$99K
1,572 services
Medicare patients, 2024
1,021
Average age 74
Drug cost, 2024
$2.4M
7,633 prescriptions
Company payments
-
None reported
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Neil D Kobrosky was code 99214 (office e&m - established), 792 times for 478 patients. In total Neil D Kobrosky billed 1,572 services in 7 codes, and Medicare paid $99K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2009-11-17.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 792 | 478 | $68.25 | $54K |
| 99213 Office E&M - Established | Facility | 589 | 515 | $46.50 | $27K |
| 99204 Office E&M - New | Facility | 146 | 146 | $95.67 | $14K |
| 99442 Telephone Services | Office | 19 | 17 | $62.55 | $1,188 |
| 99222 Hospital E&M - Initial | Facility | 14 | 14 | $102.62 | $1,437 |
By year: 2022 $115K for 1,741 services; 2023 $106K for 1,586 services; 2024 $99K for 1,572 services.
Medicare prescription drug claims, 2024
In 2024, the drug Neil D Kobrosky prescribed most often to Medicare patients was Levothyroxine Sodium, with 1,477 prescriptions and refills. In total Neil D Kobrosky wrote 7,633 Medicare prescriptions that cost $2.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 1,477 | 4,133 | 407 | $18K |
| Glipizide Er Glipizide | 616 | 1,632 | 170 | $14K |
| Metformin Hcl Er Metformin Hcl | 528 | 1,480 | 154 | $7,230 |
| Trulicity Dulaglutide | 328 | 561 | 79 | $529K |
| Ozempic Semaglutide | 308 | 555 | 77 | $506K |
| Synthroid Levothyroxine Sodium | 241 | 671 | 68 | $21K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 185 | 368 | 63 | $39K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 159 | 434 | 68 | $16K |
| Metformin Hcl Generic | 158 | 432 | 44 | $1,789 |
| Testosterone Cypionate Generic | 140 | 140 | 21 | $3,404 |
| Mounjaro Tirzepatide | 139 | 184 | 24 | $191K |
| Testosterone Generic | 134 | 137 | 19 | $15K |
| Jardiance Empagliflozin | 130 | 310 | 35 | $174K |
| Liothyronine Sodium Generic | 112 | 335 | 32 | $11K |
| Ultra-Fine Short Pen Needle Pen Needle, Diabetic | 107 | 308 | 45 | $11K |
Brand drugs: 2,967 claims; generic drugs: 4,066 claims.
Money and other things of value reported by the companies
No payments from drug or medical device companies to Neil D Kobrosky were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.